Light-targeted drug delivery
Light-targeted drug delivery
批准号:
8290898
负责人:
Matthew C Hartman
金额:
$41.8万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-04-01 至 2016-03-31
关键词:
AddressAdenocarcinoma CellAdverse effectsAlkanesulfonatesAnimalsAntibodiesAntineoplastic AgentsArginineBackBiological AssayBone Marrow CellsCancer cell lineCancerousCardiac MyocytesCathepsins BCell DeathCell membraneCell-Matrix JunctionCellsChemotherapy-Oncologic ProcedureCircular DichroismConfocal MicroscopyCytotoxic agentDevelopmentDoxorubicinDrug Delivery SystemsEndothelial CellsEnvironmentEsophageal AdenocarcinomaExtravasationFaceFibroblastsFlow CytometryFluorescenceFutureGoalsHypoxiaInhibitory Concentration 50KineticsLeadLightLightingLinkMalignant neoplasm of esophagusMeasuresMediatingMetabolismMethodsMolecularMonitorNormal CellOxygenPatientsPenetrationPeptide HydrolasesPeptidesPermeabilityPharmaceutical PreparationsPhotochemotherapyPhotosensitizing AgentsProblem SolvingProcessProdrugsProteinsRelianceResearchResolutionSideSinglet OxygenSourceSpecificitySurfaceTherapeuticTimeTissuesToxic effectTumor TissueWorkazobenzenebasecancer cellcancer therapycellular targetingchemotherapeutic agentclinical applicationcytotoxiccytotoxicitydesignflexibilitykillingsnew technologynoveloncologypreventresearch studysmall moleculetumoruptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Many types of cancer chemotherapy suffer from severe side effects. New methods for selective delivery of potent cytotoxic agents to cancer cells are needed to solve this problem. Current approaches include targeting a drug to a cancer cell using an antibody, release of a cytotoxic compound from an inactive, prodrug form in the presence of the cancerous cell, and photodynamic therapy, where light is used to create cytotoxic singlet oxygen from an inherently non-toxic photosensitizer. This reliance on photosensitizers has drawbacks; in particular, it means that all photodynamic therapy is dependent on oxygen, a problem in hypoxic tumor microenvironments. The first objective of this proposal is the development of two versatile and oxygen independent strategies for cancer treatment based on light-enabled drug delivery. The first strategy involves attaching a drug to a cell impermeable group via a light-scissile linker. Illumination will release the free drug permitting its entry into the cell. A second strategy involves using a conformationally switchable peptide that becomes cell permeable upon illumination, allowing it to carry the drug across the cell membrane. Although in principle both of these strategies could be used to deliver many types of drugs, this proposal will focus on the anticancer chemotherapeutic doxorubicin. For both strategies, the enhancement in entry of the conjugates into esophageal adenocarcinoma cells will be monitored using flow cytometry and confocal microscopy. The IC50 values of the doxorubicin conjugates in the presence and absence of light will be determined, and spatial control of cell death by light will be established. Cell death in hypoxic environments will also be
verified. Finally, the off target-toxicity of the doxorubicin conjugates will be analyzed using cardiomyocytes, bone marrow cells, and fibroblasts. Successful implementation of light-enabled drug delivery will provide a new, powerful approach for light-targeted cancer treatment.
PUBLIC HEALTH RELEVANCE: This proposal aims to develop a new versatile method for the treatment of esophageal cancer with light. Light will be used to deliver a chemotherapeutic agent into esophageal cancer cells.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Near infrared light mediated release of doxorubicin using upconversion nanoparticles.
近红外光介导的阿霉素使用上转换纳米颗粒的释放。
DOI:
10.1039/c5cc01795e
发表时间:
2015-05-18
期刊:
Chemical communications (Cambridge, England)
影响因子:
--
作者:
[Michael Dcona M, Yu Q, Capobianco JA, Hartman MC]
通讯作者:
Hartman MC
Light induced drug release from a folic acid-drug conjugate.
光诱导的药物从叶酸 - 毒剂结合物中释放。
DOI:
10.1016/j.bmcl.2016.12.036
发表时间:
2017-02-01
期刊:
Bioorganic & medicinal chemistry letters
影响因子:
2.7
作者:
[Dcona MM, Sheldon JE, Mitra D, Hartman MC]
通讯作者:
Hartman MC
DOI:
10.1039/c2an35870k
发表时间:
2012-11-07
期刊:
The Analyst
影响因子:
--
作者:
[Hartman MC, Dcona MM]
通讯作者:
Dcona MM
Genetic code expansion to enable the development of short, diverse peptide libraries
-
批准号:10202044
-
项目类别:
-
资助金额:$7.49万
-
财政年份:2021
-
负责人:Matthew C Hartman
-
依托单位:
Genetic code expansion for the construction of beyond rule-of-5 compliant macrocyclic peptide libraries
-
批准号:10810404
-
项目类别:
-
资助金额:$1.1万
-
财政年份:2021
-
负责人:Matthew C Hartman
-
依托单位:
Genetic code expansion for the construction of beyond rule-of-5 compliant macrocyclic peptide libraries
-
批准号:10450162
-
项目类别:
-
资助金额:$24.87万
-
财政年份:2021
-
负责人:Matthew C Hartman
-
依托单位:
Genetic code expansion to enable the development of short, diverse peptide libraries
-
批准号:10353426
-
项目类别:
-
资助金额:$7.49万
-
财政年份:2021
-
负责人:Matthew C Hartman
-
依托单位:
Genetic code expansion for the construction of beyond rule-of-5 compliant macrocyclic peptide libraries
-
批准号:10673661
-
项目类别:
-
资助金额:$30.88万
-
财政年份:2021
-
负责人:Matthew C Hartman
-
依托单位:
Genetic code expansion for the construction of beyond rule-of-5 compliant macrocyclic peptide libraries
-
批准号:10652818
-
项目类别:
-
资助金额:$10.88万
-
财政年份:2021
-
负责人:Matthew C Hartman
-
依托单位:
Genetic code expansion for the construction of beyond rule-of-5 compliant macrocyclic peptide libraries
-
批准号:10278366
-
项目类别:
-
资助金额:$24.89万
-
财政年份:2021
-
负责人:Matthew C Hartman
-
依托单位:
XLF in double-strand break repair and chemo/radiosensitization
-
批准号:8627590
-
项目类别:
-
资助金额:$29.9万
-
财政年份:2013
-
负责人:Matthew C Hartman
-
依托单位:
XLF in double-strand break repair and chemo/radiosensitization
-
批准号:9031072
-
项目类别:
-
资助金额:$30.79万
-
财政年份:2013
-
负责人:Matthew C Hartman
-
依托单位:
XLF in double-strand break repair and chemo/radiosensitization
-
批准号:9235261
-
项目类别:
-
资助金额:$30.77万
-
财政年份:2013
-
负责人:Matthew C Hartman
-
依托单位:
XLF in double-strand break repair and chemo/radiosensitization
-
批准号:8504038
-
项目类别:
-
资助金额:$30.81万
-
财政年份:2013
-
负责人:Matthew C Hartman
-
依托单位:
海外基金